Retatrutide and UTIs — understanding whether this investigational triple receptor agonist can cause urinary tract infections is an important question for anyone considering or participating in a clinical trial involving this medication. Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, producing significant effects on body weight and blood glucose. As it remains unapproved by the MHRA and EMA, its full safety profile is still emerging from Phase 2 and Phase 3 trials. This article examines current evidence on retatrutide's known side effects, its relationship to UTI risk, how to recognise UTI symptoms, and when to seek medical advice.

How Retatrutide Works and Its Known Side Effects

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors; its most commonly reported side effects are gastrointestinal, including nausea, vomiting, and diarrhoea.

Retatrutide is an investigational triple receptor agonist currently undergoing clinical trials. It works by simultaneously activating three incretin and metabolic hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism of action distinguishes it from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist). By targeting all three receptors, retatrutide is designed to produce significant reductions in body weight and improvements in glycaemic control, making it a candidate for treating obesity and type 2 diabetes.

As retatrutide has not yet received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), its full safety profile is still being established through ongoing Phase 2 and Phase 3 clinical trials. Based on data published to date — including a Phase 2 obesity trial published in the New England Journal of Medicine (Jastreboff et al., 2023) and a Phase 2 type 2 diabetes trial published in The Lancet (Rosenstock et al., 2023) — the most commonly reported side effects are gastrointestinal in nature. These include:

• Nausea (particularly during dose escalation)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects are broadly consistent with the class effects seen with other GLP-1-based therapies. Trial data have also noted a transient, modest increase in heart rate, and mild elevations in pancreatic enzymes (lipase and amylase) in some participants. Gallbladder-related events, including cholelithiasis, have been observed in early trial data, consistent with class-related signals seen with other GLP-1-based weight-loss therapies; however, causality for retatrutide specifically has not been established. Pancreatitis and gallbladder disease are recognised class-safety signals with GLP-1-based agents, and the evidence base for retatrutide in this regard is still emerging. Less commonly, participants have reported fatigue and injection site reactions.

Because retatrutide remains investigational, patients in the UK would only encounter it within the context of a regulated clinical trial, and it is not currently available through standard NHS or private prescribing channels. Do not attempt to obtain retatrutide from online vendors or compounding pharmacies; products sold outside regulated trials are unlicensed, unverified, and potentially unsafe.

Is There a Link Between Retatrutide and UTIs?

There is no established causal link between retatrutide and UTIs; unlike SGLT-2 inhibitors, retatrutide does not act on the kidneys in a way expected to increase urinary infection risk.

Urinary tract infections (UTIs) are not among the primary adverse effects highlighted in published retatrutide trial data to date. Unlike sodium-glucose cotransporter-2 (SGLT-2) inhibitors — a separate class of diabetes medication associated with an increased risk of genital mycotic infections (such as thrush) and, to a lesser and more variable extent depending on the individual agent, urinary tract infections — retatrutide does not act on the kidneys in a way that would be expected to directly predispose individuals to urinary infections. For reference, the Summary of Product Characteristics (SmPC) for dapagliflozin (Forxiga), available via the electronic Medicines Compendium (eMC), illustrates the infection profile typical of this drug class. There is currently no established pharmacological link between retatrutide and an increased incidence of UTIs.

It is worth noting that individuals with poorly controlled type 2 diabetes are already at elevated risk of UTIs due to glucosuria, impaired immune function, and autonomic neuropathy affecting bladder emptying. If retatrutide improves glycaemic control over time, this background risk may in fact be reduced rather than increased — though this has not been specifically studied for retatrutide.

Some speculative mechanisms — such as immunomodulatory effects of GLP-1 receptor agonism or indirect effects of significant weight loss on infection susceptibility — have been raised in preclinical research, but there is currently no robust human clinical evidence linking these mechanisms to meaningful changes in UTI risk. Such speculation is therefore not a basis for clinical concern at this stage.

In summary, there is no established causal link between retatrutide and UTIs based on current evidence. Any UTI occurring during retatrutide use should be assessed on its own clinical merits rather than automatically attributed to the medication.

Recognising Urinary Tract Infection Symptoms

UTI symptoms include burning on urination, increased urinary frequency, cloudy or malodorous urine, and lower abdominal pain; fever and back pain suggest possible kidney involvement requiring prompt assessment.

Whether or not a medication is involved, being able to recognise the symptoms of a UTI is important for prompt treatment and to prevent complications. UTIs are among the most common bacterial infections in the UK, affecting people of all ages, though they are significantly more prevalent in women due to anatomical differences. The NHS describes the typical symptoms of a lower UTI (affecting the bladder, also known as cystitis) as:

• A burning or stinging sensation when passing urine

• Needing to urinate more frequently or urgently than usual

• Urine that appears cloudy, dark, or has an unusual smell

• Pain or pressure in the lower abdomen or pelvis

• Feeling generally unwell or fatigued

Full symptom information is available on the NHS UTI page.

In older adults, UTIs may present atypically — sometimes with confusion, agitation, or a sudden change in behaviour rather than the classic urinary symptoms. This can make diagnosis more challenging and underscores the importance of clinical assessment.

If the infection spreads to the kidneys (pyelonephritis), symptoms become more severe and may include a high temperature (fever of 38°C or above), shivering or rigors, back or flank pain, nausea, and vomiting. This represents a more serious condition requiring prompt medical attention (see the section below on when to seek help).

For individuals with diabetes — a population likely to be using medications such as retatrutide — UTIs can be more frequent, more severe, and harder to treat. Maintaining good hydration, practising appropriate hygiene, and monitoring for early symptoms are all sensible preventive measures.

For uncomplicated lower UTIs in eligible individuals, NICE guideline NG109 (Urinary tract infection (lower): antimicrobial prescribing) supports a short course of antibiotics, which may be prescribed by a GP or, for women aged 16–64 without red-flag features, supplied via a community pharmacy under the NHS Pharmacy First service in England (or equivalent devolved nation schemes). This pathway applies only to uncomplicated cases meeting local protocol criteria.

When to Seek Medical Advice During Treatment

Seek same-day medical assessment if you develop fever, rigors, or back pain during retatrutide treatment, and report all new symptoms to your trial team as required by clinical trial protocol.

If you are participating in a clinical trial involving retatrutide and develop symptoms suggestive of a UTI, follow the reporting procedures outlined by your trial team. Clinical trial protocols require participants to report any new symptoms or health changes to the trial investigators, who will assess whether the symptom may be related to the study medication and ensure appropriate care is provided. Do not delay seeking help in the hope that symptoms will resolve on their own.

More broadly, there are certain situations in which you should seek prompt medical advice, regardless of whether you are on an investigational medication:

• Symptoms of a UTI that do not improve within 48 hours — contact your GP or use NHS 111

• Fever (38°C or above), rigors (shivering), or back/flank pain — these may indicate a kidney infection (pyelonephritis) and warrant same-day medical assessment; if you also experience confusion, severe drowsiness, or feel very unwell, call 999 or go to A&E, as these may be signs of sepsis

• Blood in the urine (haematuria) — this always warrants medical assessment; if haematuria persists after a UTI has been treated, your GP should refer you for further investigation in line with NICE guideline NG12 (Suspected cancer: recognition and referral), which sets out urgent referral criteria for visible haematuria

• Recurrent UTIs (two or more in six months, or three or more in a year)

• UTI symptoms in men, pregnant women, or children, as these groups require more careful evaluation

• Symptoms occurring alongside new or worsening gastrointestinal side effects from your medication

For those managing type 2 diabetes or obesity alongside an investigational therapy, maintaining regular contact with your GP or diabetes care team is advisable. Changes in blood glucose levels, weight, or general wellbeing should be communicated to your healthcare team so that your overall management plan can be reviewed and adjusted as needed. NICE guideline NG28 (Type 2 diabetes in adults: management) and current NICE obesity guidance emphasise the importance of regular monitoring and a multidisciplinary approach to care.

Reporting Side Effects to Your GP or MHRA

Clinical trial participants must report suspected adverse events to their trial team first; suspected reactions to licensed medicines outside trials can be reported via the MHRA Yellow Card scheme.

Reporting suspected side effects is a vital part of medicines safety in the UK, and this principle applies equally to investigational treatments used within clinical trials.

If you are a clinical trial participant, the first and primary point of contact for any suspected adverse event must always be your trial team or principal investigator. Clinical trials are governed by strict regulatory frameworks overseen by the MHRA, and all adverse events — including serious adverse events — must be reported and investigated by the trial sponsor and investigators in accordance with Good Clinical Practice (GCP) guidelines and MHRA pharmacovigilance requirements. Your trial team is best placed to assess causality, manage your safety, and fulfil the mandatory regulatory reporting obligations. Further information on safety reporting requirements in clinical trials is available via MHRA guidance on clinical trial safety reporting.

For healthcare professionals and members of the public reporting suspected adverse reactions to licensed or unlicensed medicines used in routine clinical care (outside of a clinical trial), the MHRA operates the Yellow Card scheme, available at yellowcard.mhra.gov.uk. This scheme allows anyone to report suspected adverse reactions to medicines, vaccines, and medical devices, and contributes to the broader evidence base that helps regulators identify safety signals.

Your GP should also be kept informed of any new symptoms or concerns during treatment. They can:

• Assess and treat any active infection, such as a UTI

• Liaise with your trial team if necessary

• Review your overall health in the context of your treatment

• Submit a Yellow Card report on your behalf if appropriate for medicines used in routine care

Open communication between patients, trial investigators, and primary care teams is essential to ensuring safe and well-monitored use of any new therapeutic agent.

Frequently Asked Questions